Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ABT with free AI briefings, catalyst countdowns, and dilution alerts.

ABT · ABBOTT LABORATORIES

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$4.3B Cash on Hand
CF+ Cash Runway
Follow ABT by email Get an email when ABT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ABT, unsubscribe in one click. Privacy

📣 What ABT Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Multiple daily injections of insulin Type 1 Diabetes N/A · NCT07423637 Recruiting
Inotropic Support Cardiogenic Shock N/A · NCT04682483 Recruiting
Vasopressor Cardiogenic Shock N/A · NCT04682483 Recruiting

Also used in these trials (approved or third-party drugs, not ABT's own candidates): Sotagliflozin.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ABT holds $4.3B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABT files for a raise →

👥 Who Owns ABT

Insiders 0.5% Institutions (3880 holders) 83.4% Public and other holders 16.1%
HolderTypeShares% of sharesAs of
Vanguard Capital Management Institution (13G, 5%+) 130,676,776 7.55% 2026-03-31
Daniel J Starks
Director · +7,105 options
Insider 6,751,361 0.39% 2026-04-24
Robert B Ford
CHAIRMAN AND CEO, Director
Insider 522,664 0.03% 2026-08-25
Daniel Gesua Sive Salvadori
EVP AND GROUP PRESIDENT
Insider 146,377 0.01% 2026-02-27
Mary K Moreland
EXECUTIVE VICE PRESIDENT
Insider 118,136 0.01% 2026-11-05
Philip P Boudreau
EVP AND CFO
Insider 82,316 0.00% 2026-09-01
Kevin T Conroy
Director · +551 options
Insider 81,230 0.00% 2026-09-23
Christopher J Scoggins
EXECUTIVE VICE PRESIDENT
Insider 77,126 0.00% 2026-02-27
Louis H. Morrone
EXECUTIVE VICE PRESIDENT
Insider 70,724 0.00% 2026-08-11
Nancy McKinstry
Director · +2,305 options
Insider 41,010 0.00% 2026-04-24
Eric Shroff
Senior Vice President
Insider 39,164 0.00% 2026-02-27
Elizabeth C. Cushman
EVP, GC AND SECRETARY
Insider 38,013 0.00% 2026-06-27

Share count 1,731,941,601 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ABT picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABT and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.